Bone Morphogenetic Protein-7 and disease progression in renal amyloidosis patients

Renal Failure

Volumn 35, Issue 8, 2013, Pages 1112-1115

  Denizli, Nazim ^a   Azak, Alper ^b   Şakaci, Murat ^b   Huddam, Bülent ^b   Koçak, Gülay ^b   Akdoǧan, Mehmet Fatih ^a   Demirci, Recep ^a   Gücün, Murat ^a   Ortabozkoyun, Levent ^b   Fidan, Yasemin ^b   Akdaǧ, Ibrahim ^b   Duranay, Murat ^b  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bone Morphogenetic Protein 7; Chronic kidney disease; Disease progression; Renal amyloidosis

Indexed keywords

CREATININE; OSTEOGENIC PROTEIN 1;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY;

ADULT; AMYLOIDOSIS; BLOOD PRESSURE; BONE MORPHOGENETIC PROTEIN 7; CREATININE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; YOUNG ADULT;

EID: 84881572012     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.815106     Document Type: Article

References (15)

1. Dirks JH, de Zeeuw D, Agarwal SK, et al. Prevention of chronic kidney and vascular disease: toward global health equity - the Bellagio 2004 Declaration. Kidney Int Suppl. 2005; 98: S1-S6.
2. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002; 13: S37-S40.
3. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol. 2009; 5: 677-689.
4. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006; 17: 3458.
5. Nguyen TQ, Goldschmeding R. Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm Res. 2008; 25(10): 2416-2426.
6. Biyikli NK, Tugtepe H, Cakalagaoglu F, et al. Downregulation of the expression of bone morphogenetic protein 7 in experimental pyelonephritis. Pediatr Nephrol. 2005; 20: 1230-1236.
7. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol. 2003; 285: F1060-F1067.
8. Duranay M, Segall L, Sen N, et al. Bone morphogenic protein-7 serum level decreases significantly in patients with contrastinduced nephropathy. Int Urol Nephrol 2011; 43: 807-812.
9. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int. 1997; 51(6): 1908-1919.
10. Schwarz S, Trivedi BK, Kalantar-Zadeh K, et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1(4): 825-831.
11. Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007; 22: 2909-2916.
12. Loghman-Adham M. Role of phosphate retention in the progression of renal failure. Lab Clin Med. 1993; 122(1): 16-26.
13. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int. 2003; 64(5): 1653-1661.
14. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008; 19(12): 2407-2413.
15. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011; 6(8): 1887-1894.